The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg.
GLP-1 drugs encourage the production of hormones that cause weight loss through reduced appetite.
Nevertheless, Berenberg's analysts believe the bigger, underappreciated, near-term opportunity lies with companies preparing to launch generic versions of the first-generation GLP-1 drugs.
Under-the-radar picks Sartorius and SKAN Group, Berenberg's "under-the-radar" pick, are also expected to benefit from manufacturing generic GLP-1 drugs.
The investment bank sees Sartorius benefiting from the growing commercialization of GLP-1 drugs and forecasts shares to rise by 27% over the next 12 months.
Persons:
Eli Lilly, Novo, Sandoz, Berenberg
Organizations:
Novo Nordisk, —, Nordisk, Novo Nordisk's Victoza, SKAN
Locations:
Germany, Europe, Sandoz, United States